A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer

被引：1

作者：

Gill, Harpaul S. ^{[1
]}

Ramalingam, Suresh S. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, 1365 Clifton Rd NE,Bldg C,Suite 4014, Atlanta, GA 30322 USA

来源：

CANCER | 2019年 / 125卷 / 13期

关键词：

durvalumab; immune checkpoint inhibition; NSCLC; PACIFIC trial; stage III NSCLC; RANDOMIZED PHASE-III; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; CONSOLIDATION DOCETAXEL; THORACIC RADIOTHERAPY; TRIAL; CHEMOTHERAPY; COMBINATION; CARBOPLATIN;

D O I：

10.1002/cncr.31996

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Overall survival data from the PACIFIC trial have reaffirmed earlier US Food and Drug Administration approval of durvalumab in patients with stage III non-small cell lung cancer. In the current commentary, the authors provide a brief historical perspective on stage III disease as well as a further analysis of the strengths and weaknesses of the trial.

引用

页码：2148 / 2153

页数：6

共 50 条

[31] Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database
Eric D Miller
James L Fisher
Karl E Haglund
John C Grecula
Meng Xu-Welliver
Erin M Bertino
Kai He
Peter G Shields
David P Carbone
Terence M Williams
Gregory A Otterson
Jose G Bazan
Radiation Oncology, 13
[32] Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database
Miller, Eric D.
Fisher, James L.
Haglund, Karl E.
Grecula, John C.
Xu-Welliver, Meng
Bertino, Erin M.
He, Kai
Shields, Peter G.
Carbone, David P.
Williams, Terence M.
Otterson, Gregory A.
Bazan, Jose G.
RADIATION ONCOLOGY, 2018, 13
[33] Stage and treatment migration in patients with stage III non-small cell lung cancer
Hubbs, J. L.
Fatunase, T.
Hollis, D. R.
Clough, R. W.
Kelsey, C. R.
D'Amico, T. A.
Marks, L. B.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S159 - S160
[34] Clinical Impact of Histologic Type in Patients with Surgically Resected Stage II and III Non-small Cell Lung Cancer
Kim, H. R.
Yun, J. K.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S294 - S295
[35] Evaluation of Predictive Values of Naples Prognostic Score in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
Guo, Dong
Liu, Jiafeng
Li, Yanping
Li, Chao
Liu, Quan
Ji, Shengjun
Zhu, Shuchai
JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 6129 - 6141
[36] PET for Prognostic Assessment in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Yilmaz, Ufuk
Asuk, Zehra
Koparal, Hakan
Ozbilek, Engin
Korkmaz, Esra
Yalcin, Burcu
Yilmaz, Hasan
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S690 - S690
[37] Treatment outcome and safety of concurrent chemoradiation in elderly patients with unresectable Stage III non-small cell lung cancer
Kim, So Jeong
Kim, Na Young
Chung, Soojie
Choi, Jeong-Hee
Hyun, In Gyu
Kim, Junghyun
EUROPEAN RESPIRATORY JOURNAL, 2023, 62
[38] Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
Gerald SMA Kerner
Leon FA van Dullemen
Erwin M Wiegman
Joachim Widder
Edwin Blokzijl
Ellen M Driever
John WG van Putten
Jeroen JW Liesker
Tineke EJ Renkema
Remge M Pieterman
Marc JF Mertens
Thijo JN Hiltermann
Harry JM Groen
Radiation Oncology, 9
[39] Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
Kerner, Gerald S. M. A.
van Dullemen, Leon F. A.
Wiegman, Erwin M.
Widder, Joachim
Blokzijl, Edwin
Driever, Ellen M.
van Putten, John W. G.
Liesker, Jeroen J. W.
Renkema, Tineke E. J.
Pieterman, Remge M.
Mertens, Marc J. F.
Hiltermann, Thijo J. N.
Groen, Harry J. M.
RADIATION ONCOLOGY, 2014, 9
[40] The Optimal Chemotherapy for Stage III Non-Small Cell Lung Cancer Patients
Gadgeel, Shirish M.
CURRENT ONCOLOGY REPORTS, 2011, 13 (04) : 272 - 279

← 1 2 3 4 5 →